ASCO 2024: Updates in the Treatment of Advanced EGFR-Mutant NSCLC

home / frontline-forum / asco-2024-updates-in-the-treatment-of-advanced-egfr-mutant-nsclc

Following the 2024 ASCO Annual Meeting, medical oncologists review recent data and discuss the evolving treatment landscape in advanced EGFR-mutant non–small cell lung cancer (NSCLC).

Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer

EP. 1: Assessing FLAURA2's Influence: How Has It Shaped Your First-Line Treatment Strategy?

Martin Dietrich, MD, PhD;Wade Iams, MD
August 23rd 2024

Following the 2024 ASCO Annual Meeting, medical oncologists share insights on how the availability of the FLAURA2 treatment regimen has impacted the treatment of patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC).

Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer

EP. 2: Evaluating MARIPOSA’s Secondary Analysis in High-Risk Advanced EGFR-Mutant NSCLC: Practical Implications

Martin Dietrich, MD, PhD;Wade Iams, MD
August 23rd 2024

Martin Dietrich, MD, PhD, discusses the secondary analysis from MARIPOSA evaluating first-line amivantamab plus lazertinib in patients with advanced EGFR-mutant NSCLC.

Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer

EP. 3: Expert Insights from PALOMA-3: Highlights from ASCO 2024

Martin Dietrich, MD, PhD;Wade Iams, MD
August 23rd 2024

Wade T. Iams, MD, outlines insights gleaned from recently presented data from the PALOMA-3 trial in advanced EGFR-mutant non–small cell lung cancer.

Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer

EP. 4: Subcutaneous Amivantimab: Overcoming Treatment Barriers and Shaping Advanced NSCLC Strategies

Martin Dietrich, MD, PhD;Wade Iams, MD
August 23rd 2024

Focusing on treatment practices for patients with advanced EGFR-mutant NSCLC, Martin Dietrich, MD, PhD, discusses how the availability of subcutaneous amivantamab can potentially address current treatment barriers.

Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer

EP. 5: Implementing Proactive Management Strategies with Amivantamab in Clinical Practice: Expert Insights

Martin Dietrich, MD, PhD;Wade Iams, MD
August 23rd 2024

Wade T. Iams, MD, provides clinical insights on proactive management strategies for patients receiving amivantamab for advanced EGFR-mutant NSCLC.

Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer

EP. 6: Insights from TROPION-Lung05 and HERTHENA-Lung01: Perspectives on the Future Role of ADCs in Advanced EGFR-Mutant NSCLC

Martin Dietrich, MD, PhD;Wade Iams, MD
August 23rd 2024

Martin Dietrich, MD, PhD, shares expert perspectives on recent data from TROPION-Lung05 and HERTHENA-Lung01 in advanced EGFR-mutant NSCLC.

Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer

EP. 7: Other Trials and Emerging Data in EGFR-Mutant NSCLC Treatment: Anticipating the Future Treatment Landscape

Martin Dietrich, MD, PhD;Wade Iams, MD
August 23rd 2024

Medical oncologists discuss the overall research landscape in advanced EGFR-mutant NSCLC, highlighting exciting trials and emerging data in the evolving treatment space.